Opening of ATP-sensitive Potassium Channel by Insulin in the Brain-induced Insulin Secretion in Wistar Rats

Abstract

Cerebral insulin can regulate glucose homeostasis via activation of the parasympathetic nervous system, which results in the reduction of hepatic glucose output. However, the precise mechanism(s) through which cerebral insulin directly exerts an effect on insulin secretion remains unclear. In the present study, we found that cerebral administration of insulin caused an increase of plasma insulin concentration and a concomitant decrease in plasma glucose levels within one hour. These effects were blocked by vagotomy or intraperitoneal injection of 1,1-dimethyl-4-diphenylacetoxypiperidinium iodide, a specific M₃ antagonist. The mediating influence of parasympathetic activation can thus be considered. The adenosine triphosphate-sensitive potassium (K-ATP) channel is a key mediator of the cerebral action of insulin. The plasma glucose-lowering action of insulin was abolished by cerebral administration of glibenclamide or repaglinide at concentrations sufficient to block K-ATP channels. In conclusion, our findings suggest that cerebral insulin may induce insulin release by stimulating the opening of K-ATP channels, which in turn activate parasympathetic tone in pancreatic tissue.

insulin - intracerebral injection - vagotomy - ATP-sensitive potassium channel - rat

References

• 1 Wada A, Yokoo H, Yanagita T, Kobayashi H. New twist on neuronal insulin receptor signaling in health, disease, and therapeutics.  J Pharmacol Sci. 2005;  99 128-143
• 2 Plum L, Belgardt BF, Bruning JC. Central insulin action in energy and glucose homeostasis.  J Clin Invest. 2006;  116 1761-1766
• 3 Niswender KD, Baskin DG, Schwartz MW. Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis.  Trends Endocrinol Metab. 2004;  15 362-369
• 4 Plum L, Schubert M, Bruning JC. The role of insulin receptor signaling in the brain.  Trends Endocrinol Metab. 2005;  16 59-65
• 5 Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production.  Nat Med. 2002;  8 1376-1382
• 6 Pocai A, Lam TK, Gutierrez-Juarez R, Obici S, Schwartz GJ, Bryan J, Aguilar-Bryan L, Rossetti L. Hypothalamic K(ATP) channels control hepatic glucose production.  Nature. 2005;  434 1026-1031
• 7 Woods SC, Makous W, Hutton RA. Temporal parameters of conditioned hypoglycemia.  J Comp Physiol Psychol. 1969;  69 301-307
• 8 Hutton RA, Woods SC, Makous WL. Conditioned hypoglycemia: Pseudoconditioning controls.  J Comp Physiol Psychol. 1970;  71 198-201
• 9 Woods SC. Conditioned hypoglycemia: effect of vagotomy and pharmacological blockade.  Am J Physiol. 1972;  223 1424-1427
• 10 Stockhorst U, Gritzmann E, Klopp K, Schottenfeld-Naor Y, Hübinger A, Berresheim HW, Steingrüber HJ, Gries FA. Classical conditioning of insulin effects in healthy humans.  Psychosom Med. 1999;  61 424-435
• 11 Stockhorst U, Steingruber HJ, Scherbaum WA. Classically conditioned responses following repeated insulin and glucose administration in humans.  Behav Brain Res. 2000;  110 143-159
• 12 Stockhorst U, Mahl N, Krueger M, Huenig A, Schottenfeld-Naor Y, Huebinger A, Berresheim HW, Steingrueber HJ, Scherbaum WA. Classical conditioning and conditionability of insulin and glucose effects in healthy humans.  Physiol Behav. 2004;  81 375-388
• 13 Norgren R, Smith GP. Central distribution of subdiaphragmatic vagal branches in the rat.  J Comp Neurol. 1988;  273 207-223
• 14 Duttaroy A, Zimliki CL, Gautam D, Cui Y, Mears D, Wess J. Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice.  Diabetes. 2004;  53 1714-1720
• 15 Iismaa TP, Kerr EA, Wilson JR, Carpenter L, Sims N, Biden TJ. Quantitative and functional characterization of muscarinic receptor subtypes in insulin-secreting cell lines and rat pancreatic islets.  Diabetes. 2000;  49 392-398
• 16 Tang SH, Sharp GW. Identification of muscarinic receptor subtypes in RINm5F cells by means of polymerase chain reaction, subcloning, and DNA sequencing.  Diabetes. 1997;  46 1419-1423
• 17 Barlow RB, McMillen LS, Veale MA. The use of 4-diphenylacetoxy-N-(2-chloroethyl)piperidine (4-DAMP mustard) for estimating the apparent affinities of some agonists acting at muscarinic receptors in guinea-pig ileum.  Br J Pharmacol. 1991;  102 657-662
• 18 Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism.  Diabetologia. 2000;  43 533-549
• 19 Teff KL. Visceral nerves: vagal and sympathetic innervation.  JPEN J Parenter Enteral Nutr. 2008;  32 569-571
• 20 Matsuhisa M, Yamasaki Y, Shiba Y, Nakahara I, Kuroda A, Tomita T, Iida M, Ikeda M, Kajimoto Y, Kubota M, Hori M. Important role of the hepatic vagus nerve in glucose uptake and production by the liver.  Metabolism. 2000;  49 11-16
• 21 Gautam D, Han SJ, Hamdan FF, Jeon J, Li B, Li JH, Cui Y, Mears D, Lu H, Deng C, Heard T, Wess J. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo.  Cell Metab. 2006;  3 449-461
• 22 Vatamaniuk MZ, Horyn OV, Vatamaniuk OK, Doliba NM. Acetylcholine affects rat liver metabolism via type 3 muscarinic receptors in hepatocytes.  Life Sci. 2003;  72 1871-1882
• 23 Fischbach GD, Frank E, Jessell TM, Rubin LL, Schuetze SM. Accumulation of acetylcholine receptors and acetylcholinesterase at newly formed nerve-muscle synapses.  Pharmacol Rev. 1978;  30 411-428
• 24 Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action.  Exp Clin Endocrinol Diabetes. 1996;  104 1-9
• 25 Quesada I, Soria B. Intracellular location of KATP channels and sulphonylurea receptors in the pancreatic beta-cell: new targets for oral antidiabetic agents.  Curr Med Chem. 2004;  11 2707-2716

Correspondence